Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Waaaaaaaay oversold in my opinion.
BPTH delisted from the Nasdaq to the OTC. ***pps dropped 67% from .64 to .21 on 6.2 million volume.
https://otce.finra.org/otce/dailyList?viewType=Additions
BPTH.........................................................a/h
BPTH......................https://stockcharts.com/h-sc/ui?s=BPTH&p=W&b=5&g=0&id=p86431144783
...................thx..........................................
Was at $5 last week but $1.40 + 40% looks good now
wise alert already down to 3.16
$BPTH 12/19/2024, 8:26:04 AMVote approved for warrants on Dec 12https://t.co/i1Mf5Hj2kc
— THE FINAL COUNTDOWN (@THIS_TIME_X) December 19, 2024
HC Wainwright
MAKING HUGE $$$ AGAIN pic.twitter.com/aqQCm5Lyho
Resistance 1.31- 1.51 time to exit trade seems logical zone to cash $$$$$$
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
I for one cannot understand how this stock price gets whacked every single time they PR good news.
a train wreck..geez
BPTH...................................https://stockcharts.com/h-sc/ui?s=BPTH&p=W&b=5&g=0&id=p86431144783
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
The low float, today’s news and myeloid leukemia news should at least stabilize the stock if nothing else. Leukemia PR should have moved it more IMO.
And the news really hasn’t started to make its rounds yet on wire notices. Will be interesting to see what the market feels about these pretty impressive results.
Finally some good news reported today.
BPTH: Indeed!! (Both the 'Low-Float' and 'Anything-Pharma' theories are now ancient history.)
Crazy that this has traded so many shares and the PPS is still where it currently sits with an incredibly small float of less than 2 million shares….
BPTH: Only 1.56-mil. Float, which might help this too. (But not quite sure if "FLOATS", per se, are trending anymore.)
BPTH: Circa where I too grabbed it. (Just when ya think "Cancer" ain't trending anymore.)
FILLED SOME 3.34'S
MOONMAN ON THIS @ 3.50 & 3.30
BPTH: Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
BENZINGA 8:44 AM ET 5/3/2024
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BPTH: effective Feb. 23,2024 a one for 20 reverse split:
https://hedgefollow.com/upcoming-stock-splits.php
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
October 24, 2023
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:
Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead
$BPTH
Followers
|
100
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6420
|
Created
|
03/26/13
|
Type
|
Free
|
Moderators |
The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.
Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.
A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.
Patent protection for manufacturing their neutral lipid delivery system has been granted.
http://www.biopathholdings.com
This link to the company website describes their delivery technology:
http://biopathholdings.com/technology/
The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |